Department of Chemistry, University of Florida, PO Box 117200, Gainesville, FL, 32611-7200, USA.
Department of Chemistry and Biochemistry, Georgia Institute of Technology, Atlanta, GA, USA.
Anal Bioanal Chem. 2022 Jul;414(18):5549-5559. doi: 10.1007/s00216-022-03993-w. Epub 2022 Mar 26.
The vast majority of mass spectrometry (MS)-based metabolomics studies employ reversed-phase liquid chromatography (RPLC) to separate analytes prior to MS detection. Highly polar metabolites, such as amino acids (AAs), are poorly retained by RPLC, making quantitation of these key species challenging across the broad concentration ranges typically observed in biological specimens, such as cell extracts. To improve the detection and quantitation of AAs in microglial cell extracts, the implementation of a 4-dimethylaminobenzoylamido acetic acid N-hydroxysuccinimide ester (DBAA-NHS) derivatization agent was explored for its ability to improve both analyte retention and detection limits in RPLC-MS. In addition to the introduction of the DBAA-NHS labeling reagent, a uniformly (U) C-labeled yeast extract was also introduced during the sample preparation workflow as an internal standard (IS) to eliminate artifacts and to enable targeted quantitation of AAs, as well as untargeted amine submetabolome profiling. To improve method sensitivity and selectivity, multiplexed drift-tube ion mobility (IM) was integrated into the LC-MS workflow, facilitating the separation of isomeric metabolites, and improving the structural identification of unknown metabolites. Implementation of the U-C-labeled yeast extract during the multiplexed LC-IM-MS analysis enabled the quantitation of 19 of the 20 common AAs, supporting a linear dynamic range spanning up to three orders of magnitude in concentration for microglial cell extracts, in addition to reducing the required cell count for reliable quantitation from 10 to 5 million cells per sample.
基于质谱(MS)的代谢组学研究绝大多数采用反相液相色谱(RPLC)在 MS 检测之前分离分析物。极性很强的代谢物,如氨基酸(AA),在 RPLC 中保留较差,使得这些关键物质在生物样本中通常观察到的广泛浓度范围内进行定量具有挑战性,例如细胞提取物。为了提高微胶质细胞提取物中 AA 的检测和定量,探索了 4-二甲氨基苯甲酰基氨乙酸 N-羟基琥珀酰亚胺酯(DBAA-NHS)衍生试剂的实施,以提高 RPLC-MS 中的分析物保留和检测限。除了引入 DBAA-NHS 标记试剂外,在样品制备工作流程中还引入了均(U)C 标记的酵母提取物作为内标(IS),以消除伪影并实现 AA 的靶向定量以及非靶向胺亚代谢组谱分析。为了提高方法的灵敏度和选择性,将多重漂移管离子淌度(IM)集成到 LC-MS 工作流程中,有利于异构体代谢物的分离,并提高未知代谢物的结构鉴定。在多重 LC-IM-MS 分析中实施 U-C 标记的酵母提取物,能够定量微胶质细胞提取物中 20 种常见 AA 中的 19 种,支持线性动态范围跨越浓度三个数量级,此外还减少了每个样品进行可靠定量所需的细胞计数,从 1000 万到 500 万。